Treatment Emergent Central Sleep Apnea Evaluation in Patients Treated with Mandibular Advancement Device

The aim of the present cohort study was to evaluate possible occurrence central sleep apnea (CSA) in patients with obstructive (OSA) after treatment a mandibular advancement device (MAD). In this case, 56 OSA treated MAD were enrolled. Inclusion criteria age over 20 years, body mass index (BMI) less than 34 kg/m2, diagnosis confirmed by polysomnography (PSG), and therapy for OSA. Exclusion smoking, medications neurological disorders or history cervical head injury, comorbidities (arrhythmias, congenital heart disease, stroke, failure lung disease). Apnea-Hypopnea Index (AHI), Oxygen Desaturation (ODI), Obstructive Sleep Apnea (OSA), Central Mixed extracted from PSGs before (T0) three months (T1). Paired-sample t-tests Wilcoxon Signature Rank test performed differences PSG indices at T1 T0. OSA, CSA, AHI, ODI showed noticeable reduction therapy, but limited number dramatic increase TCSA. presence TECSA course is condition that should be taken into consideration when needing treat an patient.